FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378978488> ?p ?o ?g. }

• W4378978488 endingPage "116646" @default.
• W4378978488 startingPage "116646" @default.
• W4378978488 abstract "Fuzheng Kang-Ai (FZKA) decoction is mainly composed of 12 components with different types of herbs. In the last decade, FZKA has been used as an adjuvant treatment for lung cancer in clinical practice. Our previous studies have confirmed that FZKA shows a strong anti-cancer activity, significantly increases the clinical efficacy of gefitinib and reverses gefitinib resistance in non-small cell lung cancer (NSCLC). However, the molecular mechanism still needs to be further elucidated.The aim of this study was to investigate the role and mechanism by which FZKA inhibited the cell growth, proliferation and invasion of lung adenocarcinoma(LUAD) and reversed the acquired resistance of gefitinib for the therapy in LUAD.Cell viability assay and EDU assay were used for detecting of cell viability and cell proliferation. Transwell assay was performed to measure cell invasion. Western Blot and qRT-PCR were used for protein and gene expression test. The gene promoter activity was determined by dul-luciferase reporter assay. The in situ expression of protein was measured by cell immunofluorescence. Stabilized cell lines were established for stable overexpression of EZH2. Transient transfection assay was used for gene silence and overexpression. Xenograft tumors and bioluminescent imaging were used for in vivo experiments.FZKA significantly inhibited the cell viability, proliferation and cell invasion of LUAD, the combination of FZKA and gefitinib had a great synergy on the above processes. Moreover, FZKA significantly decreased EZH2 mRNA and protein expression, FZKA reversed the resistance of gefitinib by down-regulation of EZH2 protein. ERK1/2 kinase mediated the down-regulation of EZH2 reduced by FZKA. In addition, FZKA decreased the expression of Snail and EGFR by decreasing EZH2. Overexpression of Snail and EGFR significantly reversed the effect of FZKA-inhibited cell invasion and cell proliferation. More important, the combination of FZKA and gefitinib enhanced the inhibitory effect on EZH2, Snail and EGFR proteins. Furthermore, the growth inhibition and reversal of gefitinib resistance induced by FZKA were further validated in vivo. Finally, the expression and clinical correlation of EZH2,EGFR and Snail in cancer patients were further validated using bioinformatics analysis.FZKA significantly suppressed tumor progression and reversed gefitinib resistance by regulating the p-ERK1/2-EZH2-Snail/EGFR signaling pathway in LUAD." @default.
• W4378978488 created "2023-06-02" @default.
• W4378978488 creator A5006632317 @default.
• W4378978488 creator A5021628435 @default.
• W4378978488 creator A5023026042 @default.
• W4378978488 creator A5031618260 @default.
• W4378978488 creator A5043490198 @default.
• W4378978488 creator A5047721028 @default.
• W4378978488 creator A5048419560 @default.
• W4378978488 creator A5062469425 @default.
• W4378978488 creator A5076049385 @default.
• W4378978488 creator A5077068949 @default.
• W4378978488 creator A5092064099 @default.
• W4378978488 creator A5092064100 @default.
• W4378978488 date "2024-01-01" @default.
• W4378978488 modified "2023-10-14" @default.
• W4378978488 title "FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma" @default.
• W4378978488 cites W2063389925 @default.
• W4378978488 cites W2066993094 @default.
• W4378978488 cites W2153048714 @default.
• W4378978488 cites W2272204855 @default.
• W4378978488 cites W2565077351 @default.
• W4378978488 cites W2604429430 @default.
• W4378978488 cites W2744911560 @default.
• W4378978488 cites W2796295138 @default.
• W4378978488 cites W2904635368 @default.
• W4378978488 cites W2906067435 @default.
• W4378978488 cites W2906374347 @default.
• W4378978488 cites W2943940684 @default.
• W4378978488 cites W2950465399 @default.
• W4378978488 cites W2951025322 @default.
• W4378978488 cites W2971928956 @default.
• W4378978488 cites W2976235020 @default.
• W4378978488 cites W2979452452 @default.
• W4378978488 cites W2994564894 @default.
• W4378978488 cites W3005196658 @default.
• W4378978488 cites W3006197480 @default.
• W4378978488 cites W3010387843 @default.
• W4378978488 cites W3016292171 @default.
• W4378978488 cites W3035838036 @default.
• W4378978488 cites W3041349355 @default.
• W4378978488 cites W3045753156 @default.
• W4378978488 cites W3047646106 @default.
• W4378978488 cites W3089076009 @default.
• W4378978488 cites W3089915247 @default.
• W4378978488 cites W3093417536 @default.
• W4378978488 cites W3094112351 @default.
• W4378978488 cites W3095553692 @default.
• W4378978488 cites W3110795491 @default.
• W4378978488 cites W3193336834 @default.
• W4378978488 cites W3195514909 @default.
• W4378978488 cites W3204493825 @default.
• W4378978488 cites W3205685501 @default.
• W4378978488 cites W3213878195 @default.
• W4378978488 cites W4200552898 @default.
• W4378978488 cites W4220672788 @default.
• W4378978488 cites W4225493893 @default.
• W4378978488 cites W4286489449 @default.
• W4378978488 doi "https://doi.org/10.1016/j.jep.2023.116646" @default.
• W4378978488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37269912" @default.
• W4378978488 hasPublicationYear "2024" @default.
• W4378978488 type Work @default.
• W4378978488 citedByCount "0" @default.
• W4378978488 crossrefType "journal-article" @default.
• W4378978488 hasAuthorship W4378978488A5006632317 @default.
• W4378978488 hasAuthorship W4378978488A5021628435 @default.
• W4378978488 hasAuthorship W4378978488A5023026042 @default.
• W4378978488 hasAuthorship W4378978488A5031618260 @default.
• W4378978488 hasAuthorship W4378978488A5043490198 @default.
• W4378978488 hasAuthorship W4378978488A5047721028 @default.
• W4378978488 hasAuthorship W4378978488A5048419560 @default.
• W4378978488 hasAuthorship W4378978488A5062469425 @default.
• W4378978488 hasAuthorship W4378978488A5076049385 @default.
• W4378978488 hasAuthorship W4378978488A5077068949 @default.
• W4378978488 hasAuthorship W4378978488A5092064099 @default.
• W4378978488 hasAuthorship W4378978488A5092064100 @default.
• W4378978488 hasBestOaLocation W43789784881 @default.
• W4378978488 hasConcept C121608353 @default.
• W4378978488 hasConcept C142724271 @default.
• W4378978488 hasConcept C1491633281 @default.
• W4378978488 hasConcept C153911025 @default.
• W4378978488 hasConcept C2776256026 @default.
• W4378978488 hasConcept C2779438470 @default.
• W4378978488 hasConcept C2780580887 @default.
• W4378978488 hasConcept C502942594 @default.
• W4378978488 hasConcept C53227056 @default.
• W4378978488 hasConcept C54355233 @default.
• W4378978488 hasConcept C55493867 @default.
• W4378978488 hasConcept C62112901 @default.
• W4378978488 hasConcept C71924100 @default.
• W4378978488 hasConcept C86803240 @default.
• W4378978488 hasConceptScore W4378978488C121608353 @default.
• W4378978488 hasConceptScore W4378978488C142724271 @default.
• W4378978488 hasConceptScore W4378978488C1491633281 @default.
• W4378978488 hasConceptScore W4378978488C153911025 @default.
• W4378978488 hasConceptScore W4378978488C2776256026 @default.
• W4378978488 hasConceptScore W4378978488C2779438470 @default.
• W4378978488 hasConceptScore W4378978488C2780580887 @default.

• next